Stężenie białka C-reaktywnego nie koreluje ze wskaźnikiem aktywności choroby Leśniowskiego-Crohna

Introduction

The natural course of Crohn’s disease (CD) is characterized by periods of exacerbations and remissions. The exacerbations are life-threatening events which usually come unpredictably and could be prevented if early stages of flares were discovered by a non-invasive test. Therefore, it is of great importance to find a reliable indicator of existing mucosal inflammatory activity [1].
Crohn’s disease is associated with impairment of the bowel mucosal barrier and profound dysfunction of the immunological system reflected by increased activity of T lymphocytes (mostly the Th1 subpopulation). Activated Th1 cells are the source of pro-inflammatory cytokines, such as IL-6, that stimulate hepatic synthesis of C-reactive protein (CRP) [2, 3]. CRP was first described in 1930 by Tillet and Francis [4], who identified this substance in the serum of a patient infected with pneumococcal pneumonia CRP was subsequently considered an “acute phase protein” playing an important diagnostic role in infectious and inflam­matory conditions. Moreover, it has been shown that CRP is unaffected by most medications [5].
Many studies have demonstrated elevated CRP levels in patients with active CD [6-9]. It was suggested that CRP may better reflect the surface of active mucosal inflammation in CD than in ulcerative colitis [7-11]. However, a recently published study denied any correlation between CRP level and endoscopically assessed mucosal status in CD patients [12]. There is also no consensus on the role of CRP measurement in prediction of exacerbations in inflammatory bowel disease (IBD) [13].
Crohn’s Disease Activity Index (CDAI) is a numerical calculation of 8 clinical variables selected empirically and multiplied by weighting factors derived from multivariate analysis (tab. I). CDAI was developed for the National Cooperative Crohn’s Disease Study to objectively assess response to therapy among patients managed at many participating centres [14]. CDAI score below 150 indicates disease remission, of 150-219 denotes mild active disease, of 220-450 means moderately active disease, and above 450 signifies a severe flare [14, 15]. The CDAI has been criticized as a measure of illness rather than disease activity. Generally, the variables entered into CDAI lack specificity and their assessment may be easily influenced by subjective interpretation of both the patient and the gastroenterologist [14, 15]. Though imperfect, the CDAI remains the most commonly used index of severity of CD.
Taken together, the clinical significance of CDAI or CRP for estimation of the extent and activity of mucosal involvement in different stages of CD is not well established. This issue is becoming especially important in view of newly emerging tests, such as faecal measurements of calprotectin or lactoferrin [16, 17]. It is also unknown whether CDAI and CRP carry similar information on activity of CD. The aim of this study was to investigate in a large group of patients with CD the relationship between serum CRP level and disease activity measured by CDAI, taking into account clinical characteristics of these patients.

Material and methods

One hundred and forty-six consecutive patients (66 men, 80 women) in whom a diagnosis of CD was unequivocally established on the basis of clinical, radiological, endoscopic and histological criteria were prospectively included in the study, irrespective of disease activity. All patients were hospitalized in the Department of Gastroenterology and Hepatology of the Silesian Medical University in Katowice between February, 2005 and November, 2007. Demographic characteristics of patients are shown in table II.
In all patients the disease activity was determined by CDAI. The CDAI and CRP were determined at the same time according to the admittance protocol. The CRP levels were measured using a turbidimetric immunoassay.
The correlation between CRP and CDAI was calculated by Pearson’s correlation test (Excel Microsoft, 2003). A p value of < 0.05 was considered as significant. We also calculated correlations between CDAI and CRP in the following subgroups of CD patients with:
• CDAI < 150, 150-219, 220-450, > 450 points,
• disease involving exclusively the ileocaecal region vs. other locations,
• body mass index (BMI) < 20, 20-25 and > 25 kg/m²,
• ongoing treatment with corticosteroids,
• ongoing biological treatment (infliximab or adali­mumab),
• previous appendectomy,
• previous bowel resective surgery.

Results

The median CDAI score of all patients was 388 points (range 65-621). Non-active or mild form of CD was diagnosed in 20 patients (CDAI  220) and moderately or highly active disease in 126 patients (CDAI > 220). Serum CRP level above the upper limit of the normal range (5 mg/l) was found in 91 patients. The median CRP level was 8.7 mg/l (range 0.1-220 mg/l). Overall CRP and CDAI Pearson’s correlation factor was 0.184. Detailed results of correlations between CRP and CDAI in subgroups of CD patients are summarised in figures 1-3.

Discussion

The measurement of inflammatory activity in CD is important not only in clinical trials but also in the setting of everyday practice to predict the course of the disease and to monitor effects of treatment [10, 18, 19]. An ideal biomarker should be disease specific, easy to perform, non- or minimally invasive, and providing rapid and reproducible results. Endoscopic or radiological methods fulfil only in part the above targets.
Measurement of serum CRP level was proposed to differentiate between intestine inflammation and functional disorders [16, 17]. An increased interest in CRP as a marker of inflammation in CD is derived from clinical trials evaluating effects of biological agents. In patients treated with infliximab, a pre-therapeutic CRP level more than 5 mg/l was associated with 76% positive therapy response compared with only 46% found in patients with baseline CRP level lower than 5 mg/l. Similar results have been demonstrated with the use of adalimumab and anti-adhesion molecules [20-22].
Recent studies have suggested that polymorphisms in the CRP gene, located on the long arm of chromosome 1 (1q23-24), account for inter-individual differences in CRP synthesis in humans [23-25]. However, data on the effect of CRP gene polymorphisms on the level of this peptide in IBD patients provide no clear message. A recent study investigating CRP polymorphisms in IBD patients showed no apparent association with serum CRP levels [26].
In the study of Karoui et al. the correlation coefficient between CRP and CDAI, although statistically significant, was only 0.3 [6]. Our study shows an even less significant correlation between serum CRP levels and CDAI. This finding holds true not only for the whole investigated population of patients with CD, but also for subpopulations selected on the basis of disease activity, intestinal location of inflammation, administered medications, past surgery and body mass index. A weak correlation was found in CD patients showing exclusive involvement of the terminal ileum.
Mucosal healing is the best prognostic factor with respect to such outcomes as need for hospitalisation (including costly ICU treatment) and for surgery [27]. In common opinion CRP may be a more appropriate indicator of mucosal status than CDAI [2, 28-30].

Conclusions

There is no correlation between serum CRP level and CDAI. The clinical significance of both indices should be further investigated as they seem to reflect different aspects of CD-related pathology.

References

 1. Nielsen OH, Ben Vainer MD, Soeren MM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359-67.  
2. Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther 2006; 23: 655-62.  
3. Nancey S, Hamzaoui N, Moussata D, et al. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008; 53: 242.  
4. Tillett WS, Francis Jr T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-85.  
5. Gisbert JP, Gonzales-Lama Y, Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007; 30: 117-29.  
6. Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 2007; 39: 1006-10.  
7. Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement of Crohn’s disease activity index. Gut 1981; 22: 571-4.  
8. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-raective protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351-60.  
9. Sachar DB, Luppescu NE, Bodian C, et al. Erythrocyte sedimentation as a measure of Crohn’s dieses activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 643-6.
10. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with –308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-24.
11. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52: 2063.
12. Jones J, Loftus EV Jr, Pannacione R, et al. Relationship between disease activity and serum and fecal biomarkers in patents with Crohn’s disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24.
13. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13: 1100-5.
14. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-6.
15. Best WR, Becktel JM, Singleton JW, Kern Jr. Deelopment of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study (NCCDS). Gastroenterology 1976; 70: 439-44.
16. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in IBD: performance of fecal lactoferrin, calprotectin, PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008; 103: 162-9.
17. Schoepfer AM, Trummler M, Seecholzer P, et al. Discriminating IBD from IBS: comparison of the performance of fecal markers, blood leucocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-9.
18. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148: 105-9.
19. Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clinical Gastroenterol Hepatol 2006; 4: 882-7.
20. Rutgeerts P, Colombel J, Enns R, et al. Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease. Gut 2003; 52 (Suppl.): A239.
21. Sandborn WJ, Weagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53: 1485-93.
22. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
23. Szalai AJ, McCrory MA, Cooper GS, et al. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14-9.
24. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-47.
25. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77.
26. Willot S, Vermeire S, Ohresser M, et al. C-reactive protein gene polymorphisms are not associated with biological or clinical response to infliximab in Crohn's disease. Gastroenterology 2005; 128 (Suppl.): A311.
27. Fro/slie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
28. Modigliani R. Endoscopic severity index for Crohn’s disease. Gastrointest Endosc 1990; 36: 637-44.
29. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 128: 1221-9.
30. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.